A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease

Background. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). Methods. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanf...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pharmacy and therapeutics 2023-12, Vol.2023, p.1-11
Main Authors: Wang, Yu, Chen, Kai, Zhou, Su-ya, Qiao, Zi-xuan, Bao, Xiao-rong
Format: Article
Language:English
Subjects:
Allopurinol
Clinical trials
Creatinine
Females
Glomerular filtration rate
Hyperuricemia
Intervention
Kidney diseases
Medical research
Meta-analysis
Metabolism
Population studies
Research design
Rheumatism
Uric acid
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c294t-8847c58bcfa6ca4440ff465b0c83caef82068d35a6a424de18b435557046c6893
container_end_page 11
container_issue
container_start_page 1
container_title Journal of clinical pharmacy and therapeutics
container_volume 2023
creator Wang, Yu
Chen, Kai
Zhou, Su-ya
Qiao, Zi-xuan
Bao, Xiao-rong
description Background. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). Methods. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, and Web of Science databases from the inception of the databases to April 2023 to identify clinical randomized controlled trials on HUA and CKD, with comparisons between febuxostat and allopurinol as variables of interest. The meta-analysis was conducted using Stata v17.0. Results. Eighteen studies were included in this meta-analysis, encompassing a total of 1877 patients. These patients were segregated into a control group (treated with allopurinol or placebo) consisting of 1039 individuals and an experimental group (treated with febuxostat alone or a combination of febuxostat with other therapies) comprising 838 patients. The meta-analysis revealed that patients in the experimental group, treated with febuxostat, exhibited a significantly higher estimated glomerular filtration rate (eGFR) than those in the control group treated with allopurinol (weighted mean difference (WMD): 2.897, 95% CI: 1.336 to 4.458, P 
doi_str_mv 10.1155/2023/9946667
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2905399148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2905399148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c294t-8847c58bcfa6ca4440ff465b0c83caef82068d35a6a424de18b435557046c6893</originalsourceid><addsrcrecordid>eNp90E9LwzAYx_EgCs4_N19AwKPWpWmSpscxNycqetBzeZYmLtIlNUnRvRdfrB2bV08h8OH3wBehi5zc5DnnY0poMa4qJoQoD9AoLwTPaJmTQzQiVFQZK2l5jE5i_CCEiJIWI_QzwU86QTZx0G6ijdj4gKd-3UGw7h2nlcYzY7RKEXuD53rZf_uYIGFwDZ60re_6AfoWe4cfbOP0Bs97p5Id_tbhxabTYRBKry3gF0hWu2Fqe6C1CpJu8JdNKzxdBe-s-pu4tVFD1GfoyEAb9fn-PUVv89nrdJE9Pt_dTyePmaIVS5mUrFRcLpUBoYAxRoxhgi-JkoUCbSQlQjYFBwGMskbncskKznlJmFBCVsUputztdsF_9jqm-sP3YSgSa1oRXlRVzuSgrndKBR9j0Kbugl1D2NQ5qbf9623_et9_4Fc7vrKugS_7v_4FWA6Gmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2905399148</pqid></control><display><type>article</type><title>A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><creator>Wang, Yu ; Chen, Kai ; Zhou, Su-ya ; Qiao, Zi-xuan ; Bao, Xiao-rong</creator><contributor>Silvestre, Samuel ; Samuel Silvestre</contributor><creatorcontrib>Wang, Yu ; Chen, Kai ; Zhou, Su-ya ; Qiao, Zi-xuan ; Bao, Xiao-rong ; Silvestre, Samuel ; Samuel Silvestre</creatorcontrib><description>Background. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). Methods. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, and Web of Science databases from the inception of the databases to April 2023 to identify clinical randomized controlled trials on HUA and CKD, with comparisons between febuxostat and allopurinol as variables of interest. The meta-analysis was conducted using Stata v17.0. Results. Eighteen studies were included in this meta-analysis, encompassing a total of 1877 patients. These patients were segregated into a control group (treated with allopurinol or placebo) consisting of 1039 individuals and an experimental group (treated with febuxostat alone or a combination of febuxostat with other therapies) comprising 838 patients. The meta-analysis revealed that patients in the experimental group, treated with febuxostat, exhibited a significantly higher estimated glomerular filtration rate (eGFR) than those in the control group treated with allopurinol (weighted mean difference (WMD): 2.897, 95% CI: 1.336 to 4.458, P &lt; 0.001). In addition, the experimental group demonstrated significantly lower levels of serum creatinine (WMD: −17.810, 95% CI: −24.147 to −11.474, P &lt; 0.001), serum uric acid (WMD: −91.891, 95% CI: −117.609 to −66.173, P &lt; 0.001), and blood urea nitrogen (WMD: −1.284, 95% CI: −1.837 to −0.731, P &lt; 0.001). However, there was no significant difference in 24-hour urinary protein quantity (WMD: −0.198, 95% CI: −0.413 to 0.016, P = 0.070) between the two groups. Conclusion. These findings suggest that febuxostat may offer a more beneficial therapeutic option for managing CKD in hyperuricemic patients. However, the observed heterogeneity and the limited diversity of the study population warrant cautious interpretation of these results.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1155/2023/9946667</identifier><language>eng</language><publisher>Oxford: Hindawi</publisher><subject>Allopurinol ; Clinical trials ; Creatinine ; Females ; Glomerular filtration rate ; Hyperuricemia ; Intervention ; Kidney diseases ; Medical research ; Meta-analysis ; Metabolism ; Population studies ; Research design ; Rheumatism ; Uric acid</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2023-12, Vol.2023, p.1-11</ispartof><rights>Copyright © 2023 Yu Wang et al.</rights><rights>Copyright © 2023 Yu Wang et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c294t-8847c58bcfa6ca4440ff465b0c83caef82068d35a6a424de18b435557046c6893</cites><orcidid>0009-0000-4180-0723</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2905399148/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2905399148?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><contributor>Silvestre, Samuel</contributor><contributor>Samuel Silvestre</contributor><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Chen, Kai</creatorcontrib><creatorcontrib>Zhou, Su-ya</creatorcontrib><creatorcontrib>Qiao, Zi-xuan</creatorcontrib><creatorcontrib>Bao, Xiao-rong</creatorcontrib><title>A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease</title><title>Journal of clinical pharmacy and therapeutics</title><description>Background. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). Methods. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, and Web of Science databases from the inception of the databases to April 2023 to identify clinical randomized controlled trials on HUA and CKD, with comparisons between febuxostat and allopurinol as variables of interest. The meta-analysis was conducted using Stata v17.0. Results. Eighteen studies were included in this meta-analysis, encompassing a total of 1877 patients. These patients were segregated into a control group (treated with allopurinol or placebo) consisting of 1039 individuals and an experimental group (treated with febuxostat alone or a combination of febuxostat with other therapies) comprising 838 patients. The meta-analysis revealed that patients in the experimental group, treated with febuxostat, exhibited a significantly higher estimated glomerular filtration rate (eGFR) than those in the control group treated with allopurinol (weighted mean difference (WMD): 2.897, 95% CI: 1.336 to 4.458, P &lt; 0.001). In addition, the experimental group demonstrated significantly lower levels of serum creatinine (WMD: −17.810, 95% CI: −24.147 to −11.474, P &lt; 0.001), serum uric acid (WMD: −91.891, 95% CI: −117.609 to −66.173, P &lt; 0.001), and blood urea nitrogen (WMD: −1.284, 95% CI: −1.837 to −0.731, P &lt; 0.001). However, there was no significant difference in 24-hour urinary protein quantity (WMD: −0.198, 95% CI: −0.413 to 0.016, P = 0.070) between the two groups. Conclusion. These findings suggest that febuxostat may offer a more beneficial therapeutic option for managing CKD in hyperuricemic patients. However, the observed heterogeneity and the limited diversity of the study population warrant cautious interpretation of these results.</description><subject>Allopurinol</subject><subject>Clinical trials</subject><subject>Creatinine</subject><subject>Females</subject><subject>Glomerular filtration rate</subject><subject>Hyperuricemia</subject><subject>Intervention</subject><subject>Kidney diseases</subject><subject>Medical research</subject><subject>Meta-analysis</subject><subject>Metabolism</subject><subject>Population studies</subject><subject>Research design</subject><subject>Rheumatism</subject><subject>Uric acid</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNp90E9LwzAYx_EgCs4_N19AwKPWpWmSpscxNycqetBzeZYmLtIlNUnRvRdfrB2bV08h8OH3wBehi5zc5DnnY0poMa4qJoQoD9AoLwTPaJmTQzQiVFQZK2l5jE5i_CCEiJIWI_QzwU86QTZx0G6ijdj4gKd-3UGw7h2nlcYzY7RKEXuD53rZf_uYIGFwDZ60re_6AfoWe4cfbOP0Bs97p5Id_tbhxabTYRBKry3gF0hWu2Fqe6C1CpJu8JdNKzxdBe-s-pu4tVFD1GfoyEAb9fn-PUVv89nrdJE9Pt_dTyePmaIVS5mUrFRcLpUBoYAxRoxhgi-JkoUCbSQlQjYFBwGMskbncskKznlJmFBCVsUputztdsF_9jqm-sP3YSgSa1oRXlRVzuSgrndKBR9j0Kbugl1D2NQ5qbf9623_et9_4Fc7vrKugS_7v_4FWA6Gmw</recordid><startdate>20231212</startdate><enddate>20231212</enddate><creator>Wang, Yu</creator><creator>Chen, Kai</creator><creator>Zhou, Su-ya</creator><creator>Qiao, Zi-xuan</creator><creator>Bao, Xiao-rong</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M7N</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><orcidid>https://orcid.org/0009-0000-4180-0723</orcidid></search><sort><creationdate>20231212</creationdate><title>A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease</title><author>Wang, Yu ; Chen, Kai ; Zhou, Su-ya ; Qiao, Zi-xuan ; Bao, Xiao-rong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c294t-8847c58bcfa6ca4440ff465b0c83caef82068d35a6a424de18b435557046c6893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allopurinol</topic><topic>Clinical trials</topic><topic>Creatinine</topic><topic>Females</topic><topic>Glomerular filtration rate</topic><topic>Hyperuricemia</topic><topic>Intervention</topic><topic>Kidney diseases</topic><topic>Medical research</topic><topic>Meta-analysis</topic><topic>Metabolism</topic><topic>Population studies</topic><topic>Research design</topic><topic>Rheumatism</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yu</creatorcontrib><creatorcontrib>Chen, Kai</creatorcontrib><creatorcontrib>Zhou, Su-ya</creatorcontrib><creatorcontrib>Qiao, Zi-xuan</creatorcontrib><creatorcontrib>Bao, Xiao-rong</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yu</au><au>Chen, Kai</au><au>Zhou, Su-ya</au><au>Qiao, Zi-xuan</au><au>Bao, Xiao-rong</au><au>Silvestre, Samuel</au><au>Samuel Silvestre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><date>2023-12-12</date><risdate>2023</risdate><volume>2023</volume><spage>1</spage><epage>11</epage><pages>1-11</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>Background. This study was designed to assess the effects of febuxostat on the uric acid level and kidney function of hyperuricemia (HUA) patients complicated with chronic kidney disease (CKD). Methods. A computer-based search was conducted on the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, and Web of Science databases from the inception of the databases to April 2023 to identify clinical randomized controlled trials on HUA and CKD, with comparisons between febuxostat and allopurinol as variables of interest. The meta-analysis was conducted using Stata v17.0. Results. Eighteen studies were included in this meta-analysis, encompassing a total of 1877 patients. These patients were segregated into a control group (treated with allopurinol or placebo) consisting of 1039 individuals and an experimental group (treated with febuxostat alone or a combination of febuxostat with other therapies) comprising 838 patients. The meta-analysis revealed that patients in the experimental group, treated with febuxostat, exhibited a significantly higher estimated glomerular filtration rate (eGFR) than those in the control group treated with allopurinol (weighted mean difference (WMD): 2.897, 95% CI: 1.336 to 4.458, P &lt; 0.001). In addition, the experimental group demonstrated significantly lower levels of serum creatinine (WMD: −17.810, 95% CI: −24.147 to −11.474, P &lt; 0.001), serum uric acid (WMD: −91.891, 95% CI: −117.609 to −66.173, P &lt; 0.001), and blood urea nitrogen (WMD: −1.284, 95% CI: −1.837 to −0.731, P &lt; 0.001). However, there was no significant difference in 24-hour urinary protein quantity (WMD: −0.198, 95% CI: −0.413 to 0.016, P = 0.070) between the two groups. Conclusion. These findings suggest that febuxostat may offer a more beneficial therapeutic option for managing CKD in hyperuricemic patients. However, the observed heterogeneity and the limited diversity of the study population warrant cautious interpretation of these results.</abstract><cop>Oxford</cop><pub>Hindawi</pub><doi>10.1155/2023/9946667</doi><tpages>11</tpages><orcidid>https://orcid.org/0009-0000-4180-0723</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0269-4727
ispartof Journal of clinical pharmacy and therapeutics, 2023-12, Vol.2023, p.1-11
issn 0269-4727
1365-2710
language eng
recordid cdi_proquest_journals_2905399148
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); Open Access: Wiley-Blackwell Open Access Journals
subjects Allopurinol
Clinical trials
Creatinine
Females
Glomerular filtration rate
Hyperuricemia
Intervention
Kidney diseases
Medical research
Meta-analysis
Metabolism
Population studies
Research design
Rheumatism
Uric acid
title A Meta-Analysis for Comparing the Effects of Febuxostat and Allopurinol on Kidney Function in Hyperuricemia Patients Complicated with Chronic Kidney Disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T14%3A41%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Meta-Analysis%20for%20Comparing%20the%20Effects%20of%20Febuxostat%20and%20Allopurinol%20on%20Kidney%20Function%20in%20Hyperuricemia%20Patients%20Complicated%20with%20Chronic%20Kidney%20Disease&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Wang,%20Yu&rft.date=2023-12-12&rft.volume=2023&rft.spage=1&rft.epage=11&rft.pages=1-11&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1155/2023/9946667&rft_dat=%3Cproquest_cross%3E2905399148%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c294t-8847c58bcfa6ca4440ff465b0c83caef82068d35a6a424de18b435557046c6893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2905399148&rft_id=info:pmid/&rfr_iscdi=true